Oncolytic vaccinia virus as an adjuvant treatment to enhancement of chemosensitivity in human pancreatic cancer cells through overexpression of Gemcitabine transporter proteins
| Project/Area Number |
24790315
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 膵癌 / 抗癌剤耐性 / ワクシニアウイルス / ｈENT / ワクチン / 化学療法 / 腫瘍溶解性組換えワクシニアウイルス / Gemcitabine |
|---|
| Research Abstract |
This experimental study aimed to examine the potential of modified vaccinia virus in enhancement of chemosensitivity in human pancreatic cancer cells through overexpression of Gemcitabine transporter proteins to investigate the relevant underlying mechanisms. hENT expression affected tumor cell chemosensitivity to gemcitabine and tumor cell invasive capacity in different pancreatic cancer cell lines. The cytotoxic effects was significantly increased compared with the control non-cancer cell line. In mouse models, virus vaccine induced tumor regression, prolonging median and long-term survival. Higher efficacy of the virus vaccine in the pancreatic cancer suggests the use of the virus as an adjuvant treatment to complete surgical resection. These promising results justify further studies of vaccinia virus in humans as a novel treatment for pancreatic cancer.
|
Report
(3 results)
Research Products
(6 results)
